Atlas Venture Life Science Advisors
$881M 13F equity value
7 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Atlas Venture Life Science Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | 2,847,541 | $327M | 37.1% |
| DYN | Dyne Therapeutics, Inc. | 6,800,099 | $151M | 17.1% |
| SION | Sionna Therapeutics, Inc. | 2,995,602 | $132M | 15.0% |
| KLRA | Kailera Therapeutics, Inc. | 5,171,282 | $114M | 12.9% |
| IRON | Disc Medicine, Inc. | 1,513,875 | $111M | 12.6% |
| QTTB | Q32 Bio, Inc. | 2,717,106 | $35M | 3.9% |
| KRRO | Korro Bio, Inc. | 962,884 | $13M | 1.4% |
Track Atlas Venture Life Science Advisors's 13F portfolio: $881M in reported holdings, 7 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}